NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. [PDF]
Cancer MedThis study was designed to evaluate the use of NEPA (netupitant/palonosetron) plus dexamethasone with or without olanzapine for the prevention of CINV in the second cycle of chemotherapy for patients receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) who developed breakthrough CINV in their first cycle despite guideline‐directed ...
Navari RM, Bonizzoni E.
europepmc +2 more sources
Comparison of aprepitant versus ondansetron for prevention of postoperative nausea and vomiting: A systematic review and meta-analysis with trial sequential analysis. [PDF]
Indian J AnaesthBackground and Aims: Postoperative nausea and vomiting (PONV) is a common complication after surgery. Preventing PONV in high-risk patients often requires a multimodal approach combining antiemetic drugs with diverse mechanisms.
Singh MP +3 more
europepmc +2 more sources
Long-Term Use of Rimegepant 75 mg for the Acute Treatment of Migraine is Associated with a Reduction in the Utilization of Select Analgesics and Antiemetics. [PDF]
J Pain ResTerence Fullerton,1 Glenn Pixton2 1Internal Medicine and Infectious Disease, Pfizer Research and Development, Pfizer Inc., Groton, CT, USA; 2Statistics, Pfizer Inc., Groton, CT, USACorrespondence: Terence Fullerton, Internal Medicine and Infectious ...
Fullerton T, Pixton G.
europepmc +2 more sources
Inconsistency in steroid use as antiemetics in clinical trial protocols involving immune checkpoint inhibitors combined with chemotherapy. [PDF]
Cancer MedObjectives This study aims to investigate the use of steroids as antiemetics in clinical trials involving immune checkpoint inhibitors with chemotherapy.
Park SM, Kim YJ, Lee JY.
europepmc +2 more sources
Management of chemotherapy induced emesis [PDF]
Archive of Oncology, 2004 Important progress has been achieved in the last few years in the prevention of chemotherapy-induced nausea and vomiting thanks to the introduction in clinical practice first of the 5-HT3 antagonists and of the NK1 antagonists more recently.
Roila Fausto
doaj +3 more sources
Frontiers in Oncology, 2021 IntroductionThe aim of this study is to rigorously review the efficacy and safety of olanzapine in chemotherapy-induced nausea and vomiting (CINV) settings including (1) at 5- and 10-mg doses, and (2) the setting of highly emetogenic chemotherapy (HEC ...
Dong-Yang Wang +3 more
doaj +1 more source
BMC Cancer, 2021 Background Among patients with colorectal cancer (CRC) treated with oxaliplatin (L-OHP)-based chemotherapy, delayed chemotherapy-induced nausea and vomiting (CINV) have not been well controlled.
Mototsugu Shimokawa +8 more
doaj +1 more source
Risk of osteoporosis in testicular germ cell tumour survivors: A systematic review of the literature
BJUI Compass, Volume 4, Issue 1, Page 24-43, January 2023., 2023 Abstract Context Testicular germ cell tumour (TGCT) survivors are potentially at risk of developing osteoporosis, because of increased risk for disturbed bone remodelling associated with hypogonadism and anti‐cancer treatment. A number of studies show bone loss and increased fracture risk in TGCT survivors, but data are scarce.
Josephina P. M. Vrouwe +4 more
wiley +1 more source
Prophylaxis of postoperative nausea and vomiting with combination of ondansetron and dexametasone in urology: Prophylaxis of postoperative nausea and vomiting [PDF]
Serbian Journal of Anesthesia and Intensive Therapy, 2016 Introduction: Postoperative nausea and vomiting is an unpleasant, distressing and exhausting experience for patients. There are inconsistent findings concerning approach to the management of PONV and disagreement as to whether prophylaxis of PONV should ...
Gvozdić Branka +2 more
doaj +1 more source
Efficacy of the granisetron transdermal system for the control of nausea and vomiting induced by highly emetogenic chemotherapy: a multicenter, randomized, controlled trial [PDF]
The Korean Journal of Internal Medicine, 2023 Background/Aims We compared the efficacy of the granisetron transdermal system (GTS) with that of ondansetron for controlling chemotherapy-induced nausea and vomiting (CINV) in patients treated with highly emetogenic chemotherapy (HEC).
Der Sheng Sun +7 more
doaj +1 more source